0.0000 (0.0000%)
  • Bid / Lots
    0.5000/ 8
  • Ask / Lots
    0.5700/ 2
  • Open / Previous Close
    0.5799 / 0.5325
  • Day Range
    Low 0.5315
    High 0.5799
  • 52 Week Range
    Low 0.3405
    High 1.5700
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.57
09:35 ET11100.5798
09:50 ET1000.574
09:51 ET69710.57
09:55 ET2050.5789
10:00 ET128000.5789
10:02 ET2000.57
10:06 ET3000.5725
10:08 ET9000.57
10:13 ET1000.5725
10:18 ET2070.5789
10:20 ET1000.573
10:24 ET3000.57
10:27 ET1000.573
10:36 ET4000.5762
10:45 ET1000.5738
10:49 ET2000.5739
11:00 ET3000.5747
11:14 ET2000.575
12:14 ET10000.5748
12:17 ET1000.5738
12:35 ET3000.5755
12:53 ET1000.575
01:02 ET2000.575
01:08 ET3000.5745
01:11 ET16000.5685
01:13 ET160000.5619
01:15 ET11000.5619
01:26 ET1000.56
01:31 ET1000.56
01:33 ET10000.5601
01:36 ET8000.5619
01:45 ET1000.56
01:56 ET1000.56
02:00 ET1000.56
02:09 ET5000.5599
02:12 ET2000.5599
02:21 ET1000.5599
02:36 ET2000.56
03:03 ET1000.5607
03:12 ET9000.5599
03:17 ET10000.54
03:24 ET2000.5425
03:28 ET3000.5425
03:30 ET12500.54
03:32 ET6000.5325
03:35 ET1000.5325
03:55 ET112000.5315
04:00 ET5710.5325
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesASLN
Aslan Pharmaceuticals Ltd
United StatesAKTX
Akari Therapeutics PLC
United StatesFRLN
Freeline Therapeutics Holdings PLC
United StatesNXTC
NextCure Inc
United StatesMAIA
Maia Biotechnology Inc
United StatesDMAC
DiaMedica Therapeutics Inc
As of 2022-12-06

Company Information

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy in autoimmune disease. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Contact Information

83 Clemenceau Avenue, #12-03 Ue Square, Singapore 239920


Independent Chairman of the Board
Andrew Howden
Chief Executive Officer, Director
Carl Firth
Chief Operating Officer, Head of Finance
Kiran Asarpota
General Counsel
Ben Goodger
Chief Business Officer
Stephen Doyle

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.